Castle Biosciences, Inc. (CSTL) vs Henry Schein, Inc. (HSIC)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| CSTL | HSIC | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Medical Distribution |
| Size band | SMALL | MID |
| Listing | Nasdaq GM | Nasdaq GS |
| Country | United States | United States |
| Theme | diagnostics | dental-care |
| Price and returns | ||
| Last close | $33.30 | $84.51 |
| Return · 1 week | +3.53% | +0.64% |
| Return · 1 month | −7.32% | −1.72% |
| Return · 3 months | +39.39% | −1.40% |
| Return · year to date | −13.60% | +10.01% |
| Return · 1 year | +38.98% | +33.00% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −24.80% | −8.32% |
| 52-week high | $44.28 | $92.18 |
| 52-week low | $17.72 | $62.15 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $1.01B | $9.63B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $11.99M | $86.83M |
| Employees | 1,002 | 25,000 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | 24.77× |
| Price to earnings · forward | n/a (negative forward earnings) | 14.17× |
| Price to sales | 2.83× | 0.71× |
| Price to book | 2.15× | 3.01× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | 13.60× |
| Enterprise value to revenue | 2.18× | 1.08× |
| PEG ratio | — | 1.69 |
| Earnings per share · trailing | -0.64 | 3.43 |
| Profitability | ||
| Gross margin | 77.26% | 31.32% |
| Operating margin | −2.96% | 5.76% |
| Profit margin | −5.43% | 2.96% |
| Return on equity | −4.20% | 8.85% |
| Return on assets | −1.36% | 4.39% |
| Growth | ||
| Revenue growth | +20.10% | +6.70% |
| Earnings growth | — | +17.10% |
| Balance sheet and payout | ||
| Debt / equity (%) | 7.80 | 80.73 |
| Current ratio | 6.04 | 1.32 |
| Dividend yield | 0.00% | 0.00% |
| Payout ratio | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 48.64 | 45.66 |
| ADX · 14 | 15.19 | 18.77 |
| 50-day average | $33.76 | $86.85 |
| 200-day average | $28.59 | $80.89 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 4.23% | 2.39% |
The full CSTL analysis
Everything this table leaves out for Castle Biosciences, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the CSTL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full CSTL analysisThe full HSIC analysis
Everything this table leaves out for Henry Schein, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the HSIC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full HSIC analysis